We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Excellent news - ABDX seems on a roll now.
Well apart from anything, it gives us a foothold with the largest U.K. pharmacy brand, which is great for us and surely must be attractive to any potential CRO/CDMO partner ultimately looking to commercialise through the retail self test market.
So that’s now Boots, Tesco, and Superdrug we have relations with. Not bad. Not bad at all.
I get the feeling that's just the start.
If that doesn't move the SP north nothing will..
ABDX confirm launch of OEM self-tests in Boots
* Boots to sell its first own brand self-tests in stores and online across the UK provided by Abingdon Health
* The global lateral flow assay market size is expected to reach USD $23 billion by 2027.
More positive news from ABDX....
Good luck, Brighty
Very nice surprise - wasn’t expecting it to be Boots!
A bit more on VenomAid and their plans to now initiate manufacturing
https://www.venomaid.com/news/venomaid-extends-its-seed-round-to-a-total-of-1-8-m-for-affordable-and-rapid-snakebite-diagnostics
Another potential one, borne purely out of mutual reactions I’ve noticed between VenomAid Diagnostics and Yates for some time. Founded in 2018 they spent a few years developing a test for Snakebite, and in 2023 attracted $1.8m seed funding to accelerate development to market and clinical testing. That is when all the reactions started and it’s not much of a leap to think some of the seed money came, and may still be coming our way.
https://www.venomaid.com/
Latest LinkedIn post Yates liked
https://www.linkedin.com/posts/venomaid_phdoftheyear-snakebite-impact-activity-7175741991522091009-jBbP?utm_source=share&utm_medium=member_desktop
Further interesting post and comment from our Liam Currivan today regarding Eco-Flo
https://www.linkedin.com/posts/liam-currivan-8bab88135_heriot-watt-university-creates-lateral-flow-activity-7175735834115985408-xiTu?utm_source=share&utm_medium=member_desktop
In case anyone missed it by the way, at about 2.43 in the pitch link I gave earlier in this thread, LVOne talk about how their test might be priced, saying “LVOne could be sold at a maximum of £620 and still be cost effective to the U.K. Healthcare system NHS.”
Now whether or not that’s anywhere close to final pricing is anyone’s guess, and so would be our % cut as manufacturer, but talking of many hundreds of pounds for a single test gives an idea of revenue potential here. Remember, the real value of LVOne is in the massive long term cost saving resulting from earlier, even 90 minute earlier, diagnosis, and that may well be worth the NHS shelling out that kind of money. And not to forget, NHS leaders were on the panel that chose Upfront as winners.
Again just for info but a company called NordicDx, which develops aquaculture tests to monitor fish health (presumably in farms) put this out today.
https://www.linkedin.com/posts/tommy-selnes-101a9653_nordicdx-revolusjonerende-teknologi-for-activity-7175375881006104576-vdUW?utm_source=share&utm_medium=member_desktop
As you will see, it’s in Norwegian and completely innocuous, but despite that both Chris Yates and our sales Director, Liam Currivan liked it. It relates to this article which describes a new digital reader for their LFT
https://nordicdx.no/en/nordicdx-no-innovativ-fiskehelseovervaking-digitalisering-hurtigtester-lfa/
I can’t think of any reason why both these ABDX guys would react to it unless we were somehow involved. Could be wrong.
Just for info but ABDX posted a job advert for a full time Supply Chain Assistant at the beginning of the month, and for a Part Time Buyer within the supply chain yesterday
https://www.google.com/search?q=jobs+at+abingdon+health&rlz=1C1BFEM_en-gbGB1004GB1004&oq=jobs+at+abingdon+health&gs_lcrp=EgZjaHJvbWUyBggAEEUYOTIHCAEQIRigATIHCAIQIRigATIHCAMQIRigATIHCAQQIRifBTIHCAUQIRifBTIHCAYQIRifBTIHCAcQIRifBTIHCAgQIRifBTIHCAkQIRifBdIBCDU2ODNqMGo0qAIAsAIA&sourceid=chrome&ie=UTF-8&ibp=htl;jobs&sa=X&ved=2ahUKEwihrteZrv6EAxUFS0EAHV7fBVMQkd0GegQIEBAB#fpstate=tldetail&htivrt=jobs&htiq=jobs+at+abingdon+health&htidocid=u_H6W8dAPmMquULfAAAAAA%3D%3D
What exactly is behind this is anyone's guess, but both roles seem geared to the manufacturing arm of the business so it could relate to improved Salistick sales, the new OEM contract orders Yates has told us about, something else, or it could just be he's replacing staff that have left!
Pretty mundane stuff I know, but always good to be aware of these things.
Another quiet day...
The only thing that's interesting is that all but one of the transactions today have been sells, yet each of those sells was transacted at a higher price than the last. So the actual bid is rising even though all we are seeing is sells.
And I noticed in the auction this morning that we had two Direct Market Access offers for stock, one for 100,000 at 8.5, and the other at 7999 at 9.
So I am wondering if these two things might indicate a sizeable buy order in the background, although I freely admit that's outside of my competence so would appreciate any insights others might give.
We just have to be patient. Its undervalued - hopefully partnerships/orders will drive the sp up. Right now there is a lack of awareness of this stock or people have lost confidence over the years
Muck165
The thing is MHC have cash and products and ABDX have great products and need cash to support revenue strategy. Could be a good collaboration and see the two working together
Jamrock - I’ve wondered if the two might be a good fit too. And TBH me well still be working together (see the links)
https://www.abingdonhealth.com/news/acquisition-concepta-yorkshire-lateral-flow-manufacturing-site-outsource-concepta-manufacturing-requirements/
https://www.abingdonhealth.com/news/mhealth-partnership-agreement-signed-with-concepta-plc/
I’m shocked that ABDX and MHC don’t work together. MHC have many lateral flow tests and actually have around 8m in the bank largely due to Covid revenue whilst there LFT tests and blood tests bed in the wellness sector. They have there products in Boots and began life as a pregnancy test company and now ABDX have a great salistick product.
Not sure if they do anything together but wouldn’t be be a bad move if they did some sort of business that suits both parties.
Thanks for reply, certainly deserving of a deeper dive on my part - I hope it keeps rising for you in the meantime!
LOL Lucksin - you’re right, patience is a virtue, frustrating though it might be!
Give it a chance Muck, it was barely known in 2020 when it had its first opportunity to fly as a company and many of us on here know what happened the first time not helped by our dear government at the time.If you believe in Karma, things will work out this time. Abingdon seem determined and probably have many helpful connections besides the ones we are aware of.
I don't know how any company can be described as all that interesting in the beginning. Once this gets adequate media coverage and it will, it will become super sexy particularly if it achieves its first forecasted share value this year of 56p!
“been UNLIKE many other AIM CEO’s”
Sorry
Thanks HarChris and yes that will, I expect be the basic concern. And I’d be foolish to say it won’t happen.
I can only say the Yates has repeatedly expressed his distaste for dilutive raises, and has confirmed again in the interims that “ The primary objective of the Board remains to move the Company to a breakeven and cash flow positive position which it forecasts will be achieved in 2024 without the need for additional funding.”
Yates has been like many other AIM CEO’s by laying out a plan, sticking to it, and succeeding with it, and I’m struggling to recall any time when he’s made forecasts that haven’t come to pass.
I think 2024 is going to be a pivotal year for ABDX as it’s broad and diverse mix CRO/CDMO customers move into manufacturing. Manufacturing (automated in our case with currently unused capacity to make millions each month) generates revenue at far higher margins and so with that, cash will rise.
I personally cannot see a better time to get in.
Isn't Abingdon's 'problem' right now for want of a better word simply funding risk? Sure the primary objective is to reach a cash flow positive position in 2024 without additional funding but it's certainly not guaranteed and even if it was surely further capital is needed to grow the business as the cash being generated will be very modest?
Investors have been stung time and time again in recent times where any 30%+ rise has been used to get a placing away at a discount, the rns'ing of a proactive interview feels like an attempt by the CEO to boost the share price a bit so I imagine the interims have caught many people's attention (including myself) as the improvement in operations is undeniable but many will be unwilling to risk being caught on the wrong side of a placing in what is a tough, tough environment for small caps right now.
As I’ve said before, I’m just excited by the potential here! It sells itself.
So why doesn’t the market agree? Am I missing something?
Personally I just think that in the minds of the herd we’re just that boring covid company which rarely has anything to say, where the price might sometimes spike on news only to settle back in the doldrums. The message just isn’t getting out there that in fact we have turned the tanker, placing risk for 2024 has all but vanished, that we offer a market leading, knowledge leading, full function service, and have now dug the groundwork to yield a large mix of sticky clients on the cusp of commercialisation targeting a very diverse mix of applications in a growing market, to include global healthcare services, for which we can manufacture at scale and at increasing margins. And this is all against the backdrop of an overburdened NHS that badly needs to control cost and effectively triage patients, and a society where home LFT testing has become understood. And then we have massive alignment with Directors and a low free float.
The main risks as far as I see them remain with the perceived accuracy of LFT’s, which we know on here is increasing rapidly as molecular tests come on line (Note our Nina Garrett is speaking on that subject at a conference this week), and possibly the potential for Directors to take us private again (although that seems highly unlikely to me).
But I’d really love to hear any concerns others might have in case I’m suffering from confirmation bias!
...I'm sure they will!. That is fantastic research Muck165. Thank you for all you are doing to show investors the true value of Abingdon Health. I am blown away by its potential, no the path it is already striding along actually, to not only expand into a healthy , highly lucrative company of substance, but one that truly enhances global health. Being connected to 52 North and the amazing neutrocheck test, that IDAP have chosen to support, will be used by the NHS to really help cancer sufferers to avoid sepsis which is the largest threat to their treatment. I'd recommend anyone read from that link you have just sent. This investment just gets better and better.
Hopefully it looks like abingdon will be actually getting some lucrative contracts from the government in a round about way ...looking good for ongoing deals meaning cash positive. Plenty of tests that will be here forever.